Lexicon Pharmaceuticals Inc LXRX
News
New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
Novo Nordisk Begins Study of Lexicon Oral Obesity Drug

